GlassScriptPhysician profile
Avneet Vig
NPI 1750672200
$2,932.60
in general payments reported to CMS, 2019-2025
15 companies · $23.78 in 2025
The $23.78 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.49 · 2021: $582 · 2022: $1,128 · 2023: $1,114 · 2024: $62.13 · 2025: $23.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845 · Consulting Fee: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.69 |
| Consulting Fee | $355.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $900.43 | 2021-2024 | Tremfya, Stelara, Remicade |
| Glaxosmithkline, LLC. | $571.32 | 2021-2024 | Benlysta |
| Abbvie INC. | $434.36 | 2021-2023 | Rinvoq, Skyrizi |
| Amgen INC. | $176.98 | 2021-2023 | Enbrel, Otezla, Tavneos |
| Radius Health, INC. | $161.92 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $146.20 | 2021-2022 | |
| Horizon Therapeutics Plc | $132.54 | 2022-2023 | Krystexxa |
| Ucb, INC. | $106.83 | 2021-2023 | Cimzia |
| Lilly USA, LLC | $82.33 | 2020-2023 | Taltz |
| Organon LLC | $62.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $49.59 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $35.25 | 2021 | |
| Mallinckrodt Hospital Products INC. | $34.01 | 2023 | Acthar |
| Fidia Pharma USA INC. | $23.78 | 2025 | Hyalgan |
| Astrazeneca Pharmaceuticals LP | $14.73 | 2023 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avneet Vig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.